Comparative Pharmacology
Head-to-head clinical analysis: OMNIPEN AMPICILLIN versus PENICILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPEN AMPICILLIN versus PENICILLIN.
OMNIPEN (AMPICILLIN) vs PENICILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and peptidoglycan cross-linking.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation, leading to cell lysis.
250-500 mg orally every 6 hours; 500 mg to 2 g intramuscularly or intravenously every 4-6 hours.
Penicillin G: 2-4 million units IV every 4-6 hours; Penicillin V: 250-500 mg orally every 6 hours for mild to moderate infections.
None Documented
None Documented
Terminal elimination half-life is approximately 1-1.5 hours in adults with normal renal function. In neonates, it may be prolonged to 2-4 hours; in renal impairment, half-life can extend significantly (up to 8-20 hours in severe impairment).
0.5-1.0 hours in normal renal function; prolonged to 7-10 hours in anuria. Dose adjustment required in renal impairment.
Renal excretion accounts for approximately 90% of elimination, primarily via tubular secretion and glomerular filtration. Biliary/fecal excretion is minimal, <10%.
Primarily renal (60-80% unchanged via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for 10-20%.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic